Abstract
Neurodegenerative and infectious disorders related to host genetics, aging, and environment are rapidly increasing. Drugs, vaccines, or regenerative proteins offer “real” possibilities for positively affecting disease outcomes but are limited by access across the blood-brain barrier. New developments in nanomedicine and cell based drug delivery are becoming available. These discoveries can lead to improved neurological disease outcomes. Such obstacles include the toxicities inherent in the delivery systems de novo such as immuno- and neurological dysfunctions and perturbations of blood-brain barrier function. This debate by leading experts in the field highlights the promise and perils of CNS drug delivery. Click on Supplemental HTML to watch the streaming video.
Electronic supplementary material
The online version of this article (doi:10.1007/s11481-008-9103-9) contains supplementary material, which is available to authorized users.
Sources
Batrakova EV, Li S, Reynolds AD, Mosley RL, Bronich TK, Kabanov AV, Gendelman HE (2007) A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem 18:1498–1506
Gilmore JL, Yi X, Quan L, Kabanov AV (2008) Novel Nanomaterials for Clinical Neuroscience. J Neuroimmune Pharmacol. DOI 10.1007/s11481-007-9099-6
Kabanov A, Gendelman H (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Progress in Polymer Science 32:1054–1082
Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ (2006) Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 1:340–350
Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 6 Perils of CNS drug delivery (PPT 4.09 MB)
ESM 7 Promise of CNS drug delivery (PPT 220 KB)
Footnotes
Electronic supplementary material
The online version of this article (doi:10.1007/s11481-008-9103-9) contains supplementary material, which is available to authorized users.
Contributor Information
Howard E. Gendelman, Email: hegendel@unmc.edu
Alexander Kabanov, Email: akabanov@unmc.edu.
James Linder, Email: jlinder@unmc.edu.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Below is the link to the electronic supplementary material.
ESM 6 Perils of CNS drug delivery (PPT 4.09 MB)
ESM 7 Promise of CNS drug delivery (PPT 220 KB)